Biosimilar

 

Biosimilar Preclinical Development Package
The development of biosimilar drugs is a complex, multi-faceted process that presents many obstacles. Procognia offers a comprehensive solution package encompassing the entire pre-clinical development process, to assist you on a highly efficient path to achieving regulatory approval.

Procognia's state-of-the-art package comprises a synergy of validated proprietary technologies and tools to take you from clone generation, through to purified bulk product for pre-clinical studies. Every element of the Procognia package is conducted by specialist experts utilizing the highest caliber technologies and techniques. The result is a unified management of complementary processes , for a highly effective and low risk profile.

 

High Expression Clone Selection
Procognia holds the exclusive rights for a proprietary technology for high expression clone generation, developed by a technology company exploiting mRNA targeting and other technologies to increase protein synthesis in mammalian cells. This high expression technology provides yield enhancement compatible with most existing technological platforms and has been validated by leading biotech companies on their optimized expression platforms.

 The high expression technology with the wide screening for the best producer clone in combination with glycosylation pattern analysis increases the probability of identifying the most suitable clone for both productivity and biosimilarity at a very early stage of development. 

 

 Procognia High Expression Advantages

  • Highly effective mRNA targeting elements
  • Reduced COG
  • Fast time-to-market
  • High return on investment